In silico identification and virtual screening to discover potent therapeutic phytochemicals against CMT2A

Charcot-Marie-Tooth (CMT2A) neuropathies are a set of monogenic diseases that affect the peripheral nervous system. The pathogenesis of CMT2A, a disease caused by genetic mutations, is linked to impaired mitochondrial dynamics and axonal biology. Therapeutic options are still limited, with only a few drugs and other authorized or underdeveloped approaches. A ligand-based virtual screening methodology was used to identify the potential MFN promoters. The natural compound subset of the ZINC database (n = 559600) was obtained and filtered using a ligand-based virtual screening technique. The top 200 compounds were identified to have more than four features that matched the target compound. Pyrx software was used to analyze the molecular docking. Based on the number and type of important binding interactions and docking results, we selected top-20 compounds with the best binding affinities for the targeted protein. 3D-QSAR analyses were performed on potential ligands identified through molecular docking analyses to predict biological activity. The pEC50 and docking scores were used to identify the potential drugs. The ADMET analysis was used to assess the kinetic characteristics of the top two drugs. According to molecular dynamics simulation, the top compound ZINC000005313168 showed high conformational stability. Based on docking results and MD findings, the best in silico hits among the compounds investigated was ZINC000005313168. These findings suggest that the compound ZINC000005313168 could be used to treat CMT2A disease. Further in vivo and in vitro studies are required to consider the present analyses. [Display omitted] •Explores Gymnema Sylvestre's bioactive compounds for diabetes management through integrated computer-aided drug design and network pharmacology.•Identifies 397 potential targets for diabetes, highlighting AKT1, SRC, TNF, PPARG, and IL1B as crucial through network pharmacology analysis.•Demonstrates Gymnemic acid I as the most promising compound, with the lowest binding energy to AKT1, indicating strong therapeutic potential.•Utilizes molecular dynamics simulations to show Gymnemic acid I's stability and potential for therapeutic interaction.•Emphasizes the need for further in vitro, in vivo, and clinical studies to validate the antidiabetic efficacy of Gymnema Sylvestre derivatives.